Kazuhiko Nakagawa Selected Research

Leukopenia

1/2020	Comparison of Carboplatin Plus Pemetrexed Followed by Maintenance Pemetrexed With Docetaxel Monotherapy in Elderly Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer: A Phase 3 Randomized Clinical Trial.
1/2017	Phase I/II study of docetaxel combined with resminostat, an oral hydroxamic acid HDAC inhibitor, for advanced non-small cell lung cancer in patients previously treated with platinum-based chemotherapy.
2/2015	Tolerability of nintedanib (BIBF 1120) in combination with docetaxel: a phase 1 study in Japanese patients with previously treated non-small-cell lung cancer.
7/2014	A phase 1 study of linifanib in combination with carboplatin/paclitaxel as first-line treatment of Japanese patients with advanced or metastatic non-small cell lung cancer (NSCLC).
12/2010	Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer: results of a west Japan oncology group study.
8/2006	Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904).
1/2003	A phase II study of topotecan in patients with relapsed small-cell lung cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kazuhiko Nakagawa Research Topics

Disease

263	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 09/2022 - 01/2002
173	Neoplasms (Cancer) 09/2022 - 01/2002
52	Disease Progression 04/2022 - 12/2008
48	Lung Neoplasms (Lung Cancer) 09/2022 - 01/2002
24	Neutropenia 01/2022 - 01/2003
24	Neoplasm Metastasis (Metastasis) 12/2021 - 10/2003
21	Stomach Neoplasms (Stomach Cancer) 01/2021 - 05/2003
20	Diarrhea 03/2021 - 11/2006
17	Colorectal Neoplasms (Colorectal Cancer) 09/2022 - 07/2006
16	Breast Neoplasms (Breast Cancer) 01/2022 - 02/2011
16	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 05/2020 - 01/2003
16	Febrile Neutropenia 01/2020 - 11/2006
15	Interstitial Lung Diseases (Interstitial Lung Disease) 01/2022 - 04/2005
13	Adenocarcinoma of Lung 03/2021 - 02/2004
11	Nausea 01/2021 - 12/2010
11	Thrombocytopenia (Thrombopenia) 01/2020 - 01/2003
10	Pneumonia (Pneumonitis) 01/2022 - 05/2008
10	Fatigue 10/2020 - 06/2009
9	Adenocarcinoma 04/2015 - 02/2004
8	Pain (Aches) 10/2020 - 08/2011
7	Malignant Mesothelioma 06/2021 - 11/2006
7	Anemia 01/2020 - 01/2003
7	Leukopenia 01/2020 - 01/2003
7	Esophageal Neoplasms (Esophageal Cancer) 12/2019 - 11/2005
6	Carcinoma (Carcinomatosis) 01/2022 - 02/2008
6	Melanoma (Melanoma, Malignant) 01/2021 - 01/2016
6	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2021 - 02/2004
6	Exanthema (Rash) 11/2016 - 02/2009
6	Lymphoma (Lymphomas) 03/2015 - 05/2012
5	Dermatitis 02/2021 - 11/2017
5	Stomatitis 02/2021 - 10/2014
5	Paronychia 02/2021 - 10/2014
5	Vomiting 01/2021 - 12/2010
5	Anorexia 01/2020 - 05/2011
5	Fever (Fevers) 12/2019 - 06/2009
5	Hypertension (High Blood Pressure) 12/2019 - 09/2010
5	Hemorrhage 12/2018 - 02/2012

Drug/Important Bio-Agent (IBA)

81	ErbB Receptors (EGF Receptor)IBA 09/2022 - 06/2003
80	Tyrosine Kinase InhibitorsIBA 03/2022 - 06/2003
57	Gefitinib (Iressa)FDA Link 09/2022 - 06/2003
43	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2022 - 03/2007
34	Cisplatin (Platino)FDA LinkGeneric 09/2022 - 03/2002
32	Carboplatin (JM8)FDA LinkGeneric 03/2022 - 08/2006
29	Docetaxel (Taxotere)FDA Link 09/2022 - 04/2005
27	Pharmaceutical PreparationsIBA 01/2022 - 12/2004
24	NivolumabIBA 06/2022 - 01/2016
24	CrizotinibIBA 01/2021 - 10/2011
22	Pemetrexed (MTA)FDA Link 09/2022 - 11/2006
22	PlatinumIBA 06/2022 - 04/2004
22	Paclitaxel (Taxol)FDA LinkGeneric 01/2022 - 01/2002
21	Biomarkers (Surrogate Marker)IBA 04/2022 - 12/2008
20	Immune Checkpoint InhibitorsIBA 09/2022 - 01/2016
19	Anaplastic Lymphoma KinaseIBA 03/2021 - 04/2011
18	osimertinibIBA 04/2022 - 01/2017
17	AfatinibIBA 01/2022 - 06/2010
17	LigandsIBA 03/2021 - 12/2012
17	Alanine Transaminase (SGPT)IBA 03/2021 - 07/2008
16	Monoclonal AntibodiesIBA 06/2021 - 08/2009
15	Proteins (Proteins, Gene)FDA Link 03/2021 - 01/2004
15	Messenger RNA (mRNA)IBA 10/2019 - 02/2004
14	Phosphotransferases (Kinase)IBA 01/2021 - 03/2003
13	Bevacizumab (Avastin)FDA Link 01/2022 - 04/2012
13	Gemcitabine FDA Link 12/2021 - 04/2005
13	alectinibIBA 01/2021 - 06/2013
13	Irinotecan (Camptosar)FDA LinkGeneric 08/2016 - 03/2002
12	RamucirumabIBA 01/2022 - 01/2016
11	Aspartate Aminotransferases (Aspartate Transaminase)IBA 03/2021 - 11/2011
10	Fluorouracil (Carac)FDA LinkGeneric 06/2022 - 06/2007
10	pembrolizumabIBA 01/2022 - 01/2016
10	dacomitinibIBA 03/2021 - 11/2017
9	Cetuximab (Erbitux)FDA Link 01/2021 - 04/2008
9	SurvivinIBA 01/2020 - 02/2006
9	Neuregulin-1 (Neuregulin 1)IBA 12/2019 - 09/2011
9	Microtubule-Associated Proteins (Microtubule-Associated Protein 2)IBA 11/2016 - 04/2011
8	nintedanibIBA 03/2022 - 10/2010
8	Vinorelbine (Navelbine)FDA LinkGeneric 01/2022 - 08/2006
8	Etoposide (VP 16)FDA LinkGeneric 11/2016 - 11/2006
7	human ERBB2 proteinIBA 01/2022 - 05/2010
7	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 03/2002
7	Trastuzumab (Herceptin)FDA Link 01/2019 - 05/2010
6	B7-H1 AntigenIBA 12/2021 - 01/2019
6	ParaffinIBA 01/2021 - 01/2013
6	Formaldehyde (Formol)FDA Link 01/2021 - 01/2013
6	Lapatinib (GW572016)FDA Link 08/2018 - 02/2009
6	Opioid Analgesics (Opioids)IBA 10/2017 - 12/2011
5	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2021 - 08/2012
5	Antineoplastic Agents (Antineoplastics)IBA 12/2020 - 04/2004
5	AntibodiesIBA 05/2020 - 01/2012
5	sepantroniumIBA 01/2020 - 10/2008
5	AnthracyclinesIBA 10/2019 - 01/2010
5	patritumabIBA 01/2019 - 12/2014
5	EnzymesIBA 10/2018 - 01/2005
5	Dasatinib (BMS 354825)FDA Link 11/2017 - 01/2010

Therapy/Procedure

108	Therapeutics 01/2022 - 11/2005
101	Drug Therapy (Chemotherapy) 09/2022 - 03/2002
28	Radiotherapy 12/2021 - 09/2006
13	Chemoradiotherapy 06/2021 - 11/2005
12	Immunotherapy 01/2022 - 02/2004
10	Combination Drug Therapy (Combination Chemotherapy) 01/2021 - 03/2006
7	Aftercare (After-Treatment) 01/2021 - 03/2015